Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Selinexor in Alveolar Soft Part Sarcoma (AXIOM)
NCT05333458Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and selinexor in alveolar soft part sarcoma (ASPS), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Aug 2022; status: recruiting.
02
Drugs
atezolizumabselinexor
03
Conditions
alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on NCT05333458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333458.